Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Background:

• Chronic kidney disease (CKD) affects millions globally, often requiring dialysis (hemodialysis or peritoneal dialysis).
• Iron overload is a frequent complication in dialysis patients, increasing risks of cardiovascular disease and infections.
• Current iron chelators are often poorly cleared by compromised renal function, complicating iron overload management.

Purpose of the Study:

• To review the efficacy and safety of deferasirox (DFX) for managing iron overload in CKD patients on dialysis.
• To explore the benefits and challenges associated with DFX treatment in this specific patient group.
• To provide a comprehensive understanding to guide clinical practice and patient care.

Main Methods:

• Literature review of existing studies on deferasirox (DFX) in CKD patients on hemodialysis (HD) or peritoneal dialysis (PD).
• Analysis of clinical data regarding DFX efficacy, safety, and patient monitoring.
• Evaluation of challenges including cost, side effects, and clearance in renal impairment.

Main Results:

• Deferasirox (DFX) presents a potential oral treatment option for iron overload in dialysis patients.
• Limited comprehensive clinical studies exist, highlighting a need for further research on DFX's long-term efficacy and safety.
• Challenges include DFX cost, potential adverse effects, and the necessity for vigilant patient monitoring.

Conclusions:

• Deferasirox (DFX) offers a promising approach to managing iron overload in CKD patients on dialysis.
• Further rigorous clinical investigation is crucial to fully establish the safety and efficacy profile of DFX.
• Addressing DFX-related challenges is essential for optimizing its use in clinical practice.